KalVista Pharmaceuticals
KALV
KALV
128 hedge funds and large institutions have $640M invested in KalVista Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 35 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
128
Holders Change
-2
Holders Change %
-1.54%
% of All Funds
1.74%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
23
Increased
45
Reduced
35
Closed
24
Calls
$15.8M
Puts
$69K
Net Calls
+$15.7M
Net Calls Change
+$17.4M
Top Buyers
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$12.5M |
| 2 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$8.7M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$6.71M |
| 4 |
VA
VR Adviser
New York
|
+$5.24M |
| 5 |
JPMorgan Chase & Co
New York
|
+$4.4M |
Top Sellers
| 1 |
BCM
Boxer Capital Management
San Diego,
California
|
-$13.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$8.92M |
| 3 |
SC
Stempoint Capital
New York
|
-$6.99M |
| 4 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$3.48M |
| 5 |
State Street
Boston,
Massachusetts
|
-$3.43M |
